Signaling Pathways As Therapeutic Targets in Biliary Tract Cancer

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2017 Mar 11

PMID 28282502

Citations 6

Authors

Jennifer Yang

Matthew R Farren

Daniel Ahn

Tanios Bekaii-Saab

Gregory B Lesinski

Affiliations

Soon will be listed here.

Abstract

The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered: This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion: Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.

Citing Articles

PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review.

Ahmadi Asouri S, Aghadavood E, Mirzaei H, Abaspour A, Shahaboddin M Heliyon. 2024; 10(13):e33767.

PMID: 39040379 PMC: 11261894. DOI: 10.1016/j.heliyon.2024.e33767.

Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis.

Di Giacomo S, Gulli M, Facchinetti R, Minacori M, Mancinelli R, Percaccio E Pharmaceutics. 2022; 14(6).

PMID: 35745837 PMC: 9231089. DOI: 10.3390/pharmaceutics14061264.

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Kast R, Alfieri A, Assi H, Burns T, Elyamany A, Gonzalez-Cao M Cancers (Basel). 2022; 14(10).

PMID: 35626167 PMC: 9140192. DOI: 10.3390/cancers14102563.

Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention.

Di Sotto A, Di Giacomo S, Rubini E, Macone A, Gulli M, Mammola C Cells. 2020; 9(4).

PMID: 32252311 PMC: 7226839. DOI: 10.3390/cells9040858.

Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.

Simile M, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu M Medicina (Kaunas). 2019; 55(2).

PMID: 30743998 PMC: 6409688. DOI: 10.3390/medicina55020042.

References

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

Pazdur R, Royce M, Rodriguez G, Rinaldi D, Patt Y, Hoff P . Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol. 1999; 22(1):78-81. DOI: 10.1097/00000421-199902000-00019. View

Tannapfel A, Weinans L, Geissler F, Schutz A, Katalinic A, Kockerling F . Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 2000; 45(2):317-24. DOI: 10.1023/a:1005412626515. View

Choi C, Choi I, Seo J, Kim B, Kim C, Um S . Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000; 23(4):425-8. DOI: 10.1097/00000421-200008000-00023. View

Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J . Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000; 47(5):721-7. PMC: 1728101. DOI: 10.1136/gut.47.5.721. View

WALKER E, Pacold M, Perisic O, Stephens L, Hawkins P, Wymann M . Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000; 6(4):909-19. DOI: 10.1016/s1097-2765(05)00089-4. View

Ahrendt S, Rashid A, Chow J, Eisenberger C, Pitt H, Sidransky D . p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg. 2001; 7(4):426-31. DOI: 10.1007/s005340070039. View

Penz M, Kornek G, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A . Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001; 12(2):183-6. DOI: 10.1023/a:1008352123009. View

OReilly E, Stuart K, Raeburn L, Steger C, Kemeny N, Saltz L . A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 2001; 12(4):501-4. DOI: 10.1023/a:1011135014895. View

10.

Stein R . Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer. 2001; 8(3):237-48. DOI: 10.1677/erc.0.0080237. View

11.

Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K . First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer. 2001; 37(15):1833-8. DOI: 10.1016/s0959-8049(01)00214-3. View

12.

Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N . Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001; 19(20):4089-91. DOI: 10.1200/JCO.2001.19.20.4089. View

13.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield M . Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17:615-75. DOI: 10.1146/annurev.cellbio.17.1.615. View

14.

Buettner R, Mora L, Jove R . Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8(4):945-54. View

15.

Patel T . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 2:10. PMC: 113759. DOI: 10.1186/1471-2407-2-10. View

16.

Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T . Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002; 13(8):1192-6. DOI: 10.1093/annonc/mdf201. View

17.

Brognard J, Dennis P . Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ. 2002; 9(9):893-904. DOI: 10.1038/sj.cdd.4401054. View

18.

Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K . Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs. 2002; 20(3):351-6. DOI: 10.1023/a:1016209901417. View

19.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A . Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002; 21(46):7001-10. DOI: 10.1038/sj.onc.1205859. View

20.

Kang Y, Kim W, Jang J . Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002; 33(9):877-83. DOI: 10.1053/hupa.2002.127444. View